However, the BRD4 degrader dBET6 was found to block proliferation and/or survival of primary CML cells in all patients tested, including blast phase CML and CML cells exhibiting the T315I variant of BCR::ABL1. This evidence concerns the gene BRD4 and chronic myelogenous leukemia, BCR-ABL1 positive.